Management of Multidrug-Resistant Male UTI with Possible Prostatitis
For a male patient with multidrug-resistant UTI where prostatitis cannot be ruled out, initiate empiric intravenous carbapenem therapy (meropenem 1g TID or imipenem/cilastatin 0.5g TID) or novel broad-spectrum agents (ceftazidime/avibactam 2.5g TID, ceftolozane/tazobactam 1.5g TID, or meropenem-vaborbactam 2g TID) based on culture results, and treat for 14 days given the inability to exclude prostatic involvement 1.
Initial Diagnostic Approach
Obtain urine culture with antimicrobial susceptibility testing immediately 1. This is mandatory for all complicated UTIs, particularly in males where any UTI is considered complicated 1. The microbial spectrum in male UTIs includes E. coli, Proteus spp., Klebsiella spp., Pseudomonas spp., Serratia spp., and Enterococcus spp., with higher antimicrobial resistance rates than uncomplicated infections 1.
Empiric Antimicrobial Selection
For Multidrug-Resistant Organisms
The 2024 EAU guidelines explicitly state that carbapenems and novel broad-spectrum antimicrobial agents should only be considered in patients with early culture results indicating the presence of multidrug-resistant organisms 1. Your options include:
Parenteral regimens:
- Imipenem/cilastatin 0.5g TID
- Meropenem 1g TID
- Ceftolozane/tazobactam 1.5g TID
- Ceftazidime/avibactam 2.5g TID
- Cefiderocol 2g TID
- Meropenem-vaborbactam 2g TID
- Plazomicin 15 mg/kg once daily 1
Critical caveat: Do not use fluoroquinolones empirically if the patient is from a urology department or has used fluoroquinolones in the last 6 months 1. Fluoroquinolone resistance rates often exceed 10% in these populations, making them inappropriate choices.
Alternative Considerations Based on Resistance Pattern
If ESBL-producing organisms are confirmed but carbapenem-sparing is desired, ceftazidime/avibactam or meropenem/vaborbactam are preferred for KPC-carbapenemase producers 2. For MDR Pseudomonas, ceftolozane/tazobactam is the primary option 2.
For patients stable enough for oral therapy after initial parenteral treatment, oral fosfomycin-trometamol has demonstrated efficacy in male UTIs with MDR Enterobacterales, including ESBL-producers resistant to fluoroquinolones and trimethoprim/sulfamethoxazole 3. Fosfomycin achieves therapeutic intraprostatic concentrations (mean 6.5 ± 4.9 µg/g) with a prostate-to-plasma ratio of 0.67, making it viable for prostatic involvement 4.
Treatment Duration
The treatment duration must be 14 days for men when prostatitis cannot be excluded 1. This is explicitly stated in the EAU guidelines and represents a critical distinction from the 7-day regimen acceptable for uncomplicated infections. The extended duration accounts for:
- Difficulty in antibiotic penetration into prostatic tissue
- Higher rates of treatment failure with shorter courses
- Risk of chronic bacterial prostatitis development if inadequately treated
Exception: If the patient is hemodynamically stable and afebrile for at least 48 hours, a 7-day course may be considered only when there are relative contraindications to the antibiotic being administered 1. However, given MDR organisms and possible prostatitis, err toward the full 14-day course.
Tailoring Therapy
Once susceptibility results return, de-escalate to the narrowest-spectrum agent with documented activity 1. This antimicrobial stewardship principle is essential to preserve novel agents.
For ESBL-producing E. coli with urinary source: Consider aminoglycosides (gentamicin 5 mg/kg daily or amikacin 15 mg/kg daily) or intravenous fosfomycin as targeted therapy, though evidence for aminoglycosides in bacteremic UTI shows no significant difference from carbapenems but with wide confidence intervals 5.
For oral step-down therapy in stable patients: Oral fosfomycin (3g every 24-48 hours) achieved clinical and microbiological cure in 16/17 episodes of chronic bacterial prostatitis with MDR Enterobacterales, though relapse rates were notable (7/12 patients) 3. This makes it suitable for completion therapy but highlights the need for close follow-up.
Management of Underlying Factors
Appropriate management of urological abnormalities is mandatory 1. Male UTIs are inherently complicated, and the 2024 EAU guidelines classify "urinary tract infection in males" as a complicating factor itself 1. Common underlying issues include:
- Benign prostatic hyperplasia causing incomplete voiding
- Urinary tract obstruction
- Vesicoureteral reflux
- Recent instrumentation
- Foreign bodies (catheters, stents)
Perform urinary tract ultrasound with post-void residual measurement to identify obstruction, incomplete voiding, or structural abnormalities 6. If post-void residual exceeds 100 mL, IPSS score is >7, or imaging shows abnormalities, refer to urology 6.
Common Pitfalls
Underestimating treatment duration: The single most common error is treating for 7 days when prostatitis cannot be excluded. Always default to 14 days in males unless prostatitis is definitively ruled out 1.
Empiric fluoroquinolone use: Given high resistance rates in urology patients and those with prior fluoroquinolone exposure, avoid empiric use 1.
Failure to obtain cultures: Unlike uncomplicated cystitis in women, male UTIs require culture and susceptibility testing before initiating therapy 1.
Ignoring local resistance patterns: The choice between empiric agents must be based on your institution's antibiogram 1.
Inadequate follow-up: Recurrence rates are high in male UTIs, particularly with MDR organisms. Clinical and microbiological follow-up is essential 3.
Novel Agents for Carbapenem-Resistant Organisms
If carbapenem resistance is documented, ceftazidime/avibactam, meropenem/vaborbactam, or imipenem/cilastatin-relebactam are first-line options 7, 2. Cefiderocol represents an alternative for extensively drug-resistant organisms 1, 7. These agents have demonstrated efficacy in complicated UTIs caused by carbapenem-resistant Enterobacterales 5, 2.